Michał Dzikowski

Michał Dzikowski

Auto-generated profile, based on publicly available information

Michał Dzikowski

I Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin, Poland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MDMichał Dzikowski
Michał Dzikowski
DJDariusz Juchnowicz
Dariusz Juchnowicz
IDIzabela Dzikowska
Izabela Dzikowska
Joanna RogJoanna Rog
Joanna Rog
MPMichał Próchnicki
Michał Próchnicki
Hanna Karakula-JuchnowiczHanna Karakula-Juchnowicz
Hanna Karakula-Juchnowicz
Schizophrenia is a heterogeneous disorder without a fully elucidated etiology and mechanisms. One likely explanation for the development of schizophrenia is low-grade inflammation, possibly caused by processes in the gastrointestinal tract related to gluten sensitivity. The aims of this study were to: (1) compare levels of markers of gluten sensitivity, inflammation and gut permeability, and (2) determine associations between gluten sensitivity, inflammation, and intestinal permeability in patients with first-episode/chronic (FS/CS) schizophrenia and healthy individuals (HC). The total sample comprised 162 individuals (52 FS; 50 CS, and 60 HC). The examination included clinical variables, nutritional assessment, and serum concentrations of: high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), soluble CD14 (sCD14), anti-Saccharomyces cerevisiae antibody (ASCA), antigliadin antibodies (AGA) IgA/IgG, antibodies against tissue transglutaminase 2 (anti-tTG) IgA, anti-deamidated gliadin peptides (anti-DGP) IgG. A significant difference between groups was found in sCD14, ASCA, hs-CRP, IL-6 and AGA IgA levels. AGA IgG/IgA levels were higher in the FS (11.54%; 30.77%) and CS (26%; 20%) groups compared to HC. The association between intestinal permeability and inflammation in the schizophrenic patients only was noted. The risk for developing schizophrenia was odds ratio (OR) = 4.35 (95% confidence interval (CI 1.23–15.39) for AGA IgA and 3.08 (95% CI 1.19–7.99) for positive AGA IgG. Inflammation and food hypersensitivity reactions initiated by increased intestinal permeability may contribute to the pathophysiology of schizophrenia. The immune response to gluten in FS differs from that found in CS.

1 December 2021 in Current Problems of Psychiatry
Verified
Journal Article
Open access
PDF file
PSPaweł Stanicki
Paweł Stanicki
KSKlaudia Szukała
Klaudia Szukała
MSMałgorzata Szypłowska
Małgorzata Szypłowska
MDMichał Dzikowski
Michał Dzikowski
Introduction: Refeeding syndrome RS is a life-threatening acute hormonal and metabolic disorder that occurs in patients with moderate or severe malnutrition as a result of improperly administered nutritional therapy. Material and method: The aim of this study is to describe the cases of two female patients suffering from anorexia nervosa, who developed a refeeding syndrome after starting nutritional therapy. Additionally, the available literature was reviewed in order to characterize the issue, including negative consequences and prevention of the refeeding syndrome. Results: In both cases, the development of the refeeding syndrome was found in the patients, resulting from the excessive supply of energy and nutritional substrates in a short time, preceded by a previous, months long period of starvation and exhaustion of the organism (both patients had a decrease in the body mass index - BMI - to the value of about 14 kg / m2). In patient 1, the symptoms concerned mainly the cardiovascular system: a significant increase in the concentration of N-terminal B-type natriuretic propeptide (NT-proBNP) and tachycardia, as well as a decrease in the concentration of inorganic phosphates and hypokalemia. On the other hand, in the case of patient 2, symptoms such as confusion or deep disturbances of consciousness, which led to hospitalization in the intensive care unit, dominated the clinical picture. Conclusions: Refeeding syndrome may develop during nutritional rehabilitation, especially in the case of a sudden, inadequately planned supply of nutrients. Particular care should be taken in patients with extremely low BMI when reintroducing nutrition. The presented case reports draw attention to the possibility of cardiological complications and mental disorders of the realimentation syndrome, and indicate the behavior of patients (eating excessive food) that may lead to the development of the refeeding syndrome.

25 May 2022 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
MSMonika Szwed
Monika Szwed
JSJakub Szwed
Jakub Szwed
MDMichał Dzikowski
Michał Dzikowski
Introduction and purpose Botulinum toxin (BoNT) products are commonly used to treat muscle spasms such as cervical dystonia as well as to treat expression lines. Serotype A of botulinum toxin is the strongest and is used in aesthetic medicine procedures. It provides predictable results while having few side effects. Nevertheless, complications may occur, such as: ptosis of the upper eyelid, drooping eyebrows, ectropia, double vision, xerophthalmia, falling corners of the mouth, dysphagia, hoarseness, local swelling, erythema, bruising, pain at the injection site, asymmetry. The aim of the study is to discuss the most common complications after injection of the botulin toxin in the correction of mimic wrinkles. Description of the state of knowledge BoNT is a neurotoxin that acts on the neuromuscular junctions, inhibits the release of acetylcholine, consequently causing temporary chemical denervation. Muscle function begins to return approximately 3 months after injection and fully returns after 6 months. Comparison of clinical trials of botulinum toxin type A in aesthetic allowed for the quantification of the frequency of adverse effects:drooping eyelids (2.5%), drooping eyebrows (3.1%), disturbed eye sensation (3%) and lip asymmetry (6.9%). Complications after cosmetic botulinum toxin injections are rare, and those that do occur are usually mild and transient. These complications are technique dependent; the incidence decreases as the injection ability improves. Summary Side effects are rare, nevertheless, thorough knowledge of the patient's anatomy, medical history, possible complications related to the specific product and site of administration, and close monitoring are essential for safe, effective treatment and the achievement of satisfactory results.

8 September 2023 in Current Problems of Psychiatry
Verified
Journal Article
Open access
ZWZuzanna Joanna Wingralek
Zuzanna Joanna Wingralek
AMAleksandra Marczak
Aleksandra Marczak
JTJustyna Tomasik
Justyna Tomasik
AGAdrian Giermasiński
Adrian Giermasiński
MDMichał Dzikowski
Michał Dzikowski
Introduction: Borderline personality disorder (BPD) affects approximately 1%-3% of the population. As the most common personality disorder, BPD features behavioural, emotional and social dysfunctions. It often co-occurs with self-harm, suicidal tendencies and substance abuse. To date, pharmacological treatment does not provide sufficient therapeutic effects. The aim of our study is to analyse the neurobiological, genetic and environmental components in the aetiopathogenesis of BPD and to collect data on the innovative use of lithium and naltrexone in the therapy of BPD. Methods: Basing on PubMed and Google Scholar databases using the following keywords: borderline, lithium, naltrexone for papers published from 1979 to 2022. Results: Difficult childhood, and emotional, sexual and physical abuse are the strongest predictors of BPD development. The core symptoms of BPD may be related to dysfunction of the serotonin, dopaminergic, endogenous system and opioid systems. Variation in 5-HTT, COMT, FKBP5 and oxytocin receptor genes may influence the course of BPD. Imaging studies have shown structural and functional abnormalities in the prefrontal cortex, amygdala and hippocampus. Lithium reduces impulsivity, aggression, suicidal tendencies and self-harm in BPD. Naltrexone may effectively reduce self-harm without suicidal tendencies, impulsivity, substance abuse and suicidality. Conclusions: No unified model has been developed to account for environmental, genetic and neurobiological components in the pathogenesis of BPD. Understanding the mechanisms is a crucial step towards personalising treatment. The use of lithium and naltrexone may have positive therapeutic effects. Randomised clinical trials are required to establish the efficacy and safety of both drugs in long-term treatment. Keywords: borderline, lithium, naltrexone

27 December 2024 in Current Problems of Psychiatry
Verified
Journal Article
Open access
KKKlaudia Kister
Klaudia Kister
AMAgata Makarewicz
Agata Makarewicz
MDMichał Dzikowski
Michał Dzikowski
EDEwelina Drzał
Ewelina Drzał
PWPaulina Wróbel-Knybel
Paulina Wróbel-Knybel
Introduction: Depression is one of the most common mental disorders in the world, and treatment of this condition often includes the use of selective serotonin reuptake inhibitors (SSRI). Despite their widespread use and effectiveness, SSRI can cause adverse effects, especially in the pediatric and adolescent population, which requires close specialized supervision. A particularly vulnerable group are patients with autism spectrum disorders, where reactions to SSRI can be atypical and unpredictable. Purpose: The aim of this study is to report an atypical response to sertraline treatment in a minor patient with a diagnosis of Asperger's syndrome, resulting in impulsive and aggressive behavior with legal consequences. Case description: A 16-year-old patient with Asperger syndrome was treated with sertraline for depression and suicidal thoughts. Within three weeks of starting therapy, he developed severe symptoms of agitation, delusions and aggressive behavior that led to conflict with the law. The patient was referred for forensic psychiatric observation, where he was diagnosed with acute psychosis with symptoms of delusions of grandeur meeting the criteria for acute manic state F30.2. according to the ICD­10 classification. Conclusions: This case illustrates the risks of using SSRI in autistic patients, indicating the need for further studies on the safety of pharmacotherapy with this group of drugs in this population. The authors suggest special caution and the need to monitor children and adolescents taking SSRIs and to consider hospital conditions for the treatment of at-risk patients. Keywords: sertraline, SSRI, pharmacotherapy safety, ssri side effects